Recently, the research team led by Min Wang at the College of Marine Life Sciences, Ocean University of China, published a study titled " Diversity of reverse-transcriptase-containing viruses ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer ...

Now, a new study has found that nucleoside reverse transcriptase inhibitors (NRTIs) — a common class of medications for HIV — could dramatically decrease the risk of developing this ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer ...

HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA.

Through rational structure-based drug design, ROME identified novel, selective and potent inhibitors of LINE-1 reverse transcriptase.

HIV-1 Reverse Transcriptase Inhibitors Publication Trend The graph below shows the total number of publications each year in HIV-1 Reverse Transcriptase Inhibitors.

New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) comprise approximately 10% of the HIV drug market worldwide, and efavirenz leads this class with $680 million annual sales in the United ...